Premium
Infliximab for refractory ulcerative proctitis
Author(s) -
BOUGUEN G.,
ROBLIN X.,
BOURREILLE A.,
FEIER L.,
FILIPPI J.,
NANCEY S.,
BRETAGNE J.F.,
FLOURIÉ B.,
HÉBUTERNE X.,
BIGARD M.A.,
SIPROUDHIS L.,
PEYRINBIROULET L.
Publication year - 2010
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2010.04293.x
Subject(s) - infliximab , medicine , ulcerative colitis , refractory (planetary science) , proctitis , gastroenterology , rescue therapy , endoscopy , surgery , colonoscopy , tumor necrosis factor alpha , colorectal cancer , cancer , physics , disease , astrobiology
Aliment Pharmacol Ther 31 , 1178–1185 Summary Background Efficacy of infliximab in treating ulcerative proctitis remains unknown. Aim To evaluate the clinical, biological and endoscopic efficacy of infliximab therapy in refractory proctitis. Methods The charts of 420 patients treated with infliximab for ulcerative colitis were reviewed. Thirteen patients were treated with infliximab for refractory ulcerative proctitis in six referral centres between 2005 and 2009. Results Following infliximab therapy induction, 9/13 patients (69%) had a complete response (defined as absence of diarrhoea and blood), 2/13 (15%) had a partial response and 2/13 (15%) were primary nonresponders. The median follow‐up was 17 months (range, 3–48). Among the 11 patients with clinical response after infliximab induction therapy, 9 (82%) patients maintained response at last follow‐up. Disappearance of rectal disorders was observed in all nine patients who maintained clinical response at last follow‐up. Following infliximab induction therapy, the mean CRP level fell from 12.8 mg/L to 4.7 mg/L. Endoscopic evaluation was performed before and after infliximab in seven patients, showing an improvement in mucosal lesions in four patients, persistent mild endoscopic activity in two patients and no improvement in one patient. One patient underwent proctocolectomy. Conclusion Infliximab therapy seems to be effective in inducing and maintaining a clinical response in refractory ulcerative proctitis.